MedTrace Logo

Test for Pre Operative Skin Preparations

NCT00799812 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 335

Last updated 2025-12-11

Study results available
· View outcomes & findings →

Summary

Compare 2 application techniques of ChloraPrep Swabstick--3 swabsticks at once versus 3 swabsticks used sequentially. Hibiclens applied according to the manufacturer's directions. Sterile swabsticks (wetted with sterile deionizd water) applied using the same method as the ChloraPrep Swabstick.

Conditions

  • Topical Antisepsis

Interventions

DRUG

CHG 2% w/v & IPA 70% v/v, swabstick (3 @ once).

3 swabsticks topically applied at the same time to intact skin

DRUG

CHG 2% w/v & IPA 70% v/v swab applied sequentially

Chlorhexidine gluconate 2% w/v and isopropyl alcohol 70% v/v; 3 swabsticks applied sequentially to intact skin.

DRUG

Aqueous CHG 4% w/v applied according to mfr's directions

Chlorhexidine gluconate 4% w/v in an aqueous base applied according to mfr's directions. Step 1) 5 ml of Hibiclens applied to a sterile gauze pad. Step 2) Product applied to treatment area on intact skin for 2 minutes. Area dried with sterile towel or sterile gauze. Steps 1 and 2 repeated.

OTHER

Sterile swabstick with sterile water (3 @ once)

3 sterile swabsticks wetted with sterile water topically applied to intact skin at the same time.

OTHER

Sterile swabstick with sterile water (one-at-a-time)

Sterile swabsticks wetted with sterile water topically applied to intact skin one-at-a-time.

Sponsors & Collaborators

  • C. R. Bard

    lead INDUSTRY

Principal Investigators

  • M. Hamid Bashir, MD · Medical Director

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-11-13
Primary Completion
2008-04-27
Completion
2008-06-19

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00799812 on ClinicalTrials.gov